Professor of Neurology, Harvard Medical School; Translational Neurology Head and Managing Director of the Interdisciplinary Brain Center, Massachusetts General Hospital
Dr. Steven E. Arnold is a Professor of Neurology at Harvard Medical School and Translational Neurology Head and Managing Director of the Interdisciplinary Brain Center at Massachusetts General Hospital.
After receiving his M.D. from Boston University, Dr. Arnold completed residency training in Psychiatry at the New York State Psychiatric Institute / Columbia Presbyterian Medical Center in New York and residency training in Neurology at the University of Iowa Hospitals and Clinics in Iowa City. He also completed fellowship training in Cognitive Neuroscience and was a post-doctoral associate in Neuroanatomy in Iowa. Dr. Arnold is board certified in both neurology and psychiatry. After his training, Dr. Arnold joined the faculty at the University of Pennsylvania, where he was a Professor of Psychiatry and Neurology until his move to Massachusetts General Hospital in 2015. At Penn, Dr. Arnold was Director of the Penn Memory Center, Associate Director and Clinical Core Leader of the Alzheimer’s Disease Core Center, and Associate Director of the University of Pennsylvania’s Institute on Aging.
At the Massachusetts General Hospital, Dr. Arnold leads the Alzheimer’s Clinical and Translational Research Unit, conducting early-phase clinical trials and biomarker research. He is also Managing Director of the Interdisciplinary Brain Center, a new collaboration of the Departments of Neurology. Psychiatry and the Martinos Center for Neuroimaging.
Dr. Arnold has conducted longstanding research on neurodegenerative disease pathology, molecular biomarkers, and therapeutics for cognitive decline and psychiatric syndromes in late life and has led broad clinical and translational research programs. He has authored over 350 scientific articles, reviews, and chapters. Current scientific interests include biomarkers in brain aging and dementias, immune and metabolic factors driving dementia, and protective factors that account for cognitive resilience, all with the goal of accelerating therapeutics discovery and development.